ALNY - Alnylam falls 18% following Q3 2021 earnings disappointment

Shares of Alnylam Pharmaceuticals (ALNY -17.9%) are down in morning trading after the RNAi biotech missed Q3 earnings estimates on both EPS and revenue. Alnylam's YoY net loss narrowed 19% to $204.5M. Net loss per common share went to $1.72 from $2.18. Although revenue grew 49% YoY to $187.6M, that still fell ~$31M short of analyst expectations. Sales of Alnylam's best-selling drug, Onpattro (patisiran), grew 6% compared to Q3 2020 to $120M. Its next best-selling drug, Givlaari (givosiran) increased 4% to $32M. On the R&D front, Alynlam yesterday announced that its polyneuropathy associated with hereditary transthyretin-mediated (hATTR) amyloidosis drug vutrisiran met all secondary goals at 18 months in a phase 3 study. The company today also said that founding CEO John Maraganore will retire at the end of the year.

For further details see:

Alnylam falls 18% following Q3 2021 earnings disappointment